The expression of PCNA, c-erbB-2, p53, ER and PR as well as atypical hyperplasia in tissues nearby the breast cancer

Journal of Molecular Histology

Volumn 43, Issue 1, 2012, Pages 115-120

  Jia, Zongliang ^a   Zhao, Wei ^a   Fan, Lin ^a   Sheng, Wei ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Breast cancer; Breast conservative surgery; C erbB 2; Estrogen receptor; Progesterone receptor; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; C ERBB 2 GENE; CANCER GROWTH; CONTROLLED STUDY; CYCLINE GENE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; P53 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; TUMOR GENE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 85027940697     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-011-9371-1     Document Type: Article

References (13)

1. Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M (2002) C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer. Anticancer Res 22:1097-1103 (Pubitemid 34836157)
2. Khoury MP, Bourdon JC (2011) p53 Isoforms: An intracellular microprocessor? Genes Cancer 2:453-465. doi:10.1177/1947601 911408893
3. Kumar S, Walia V, Ray M, Elble RC (2007) p53 in breast cancer: mutation and countermeasures. Front Biosci 12:4168-4178
4. Law TT, Kwong A (2009) Surgical margins in breast conservation therapy: how much should we excise? Southern Med J 102:1234-1237. doi:10.1097/SMJ. 0b013e3181bfd420
5. Lopez-Guerrero JA, Navarro S, Noguera R, Almenar S, Pellin A, Vazquez C, Llombart-Bosch A (2003) Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: A comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. Arkh Patol 65:50-55 (Pubitemid 38880824)
6. Luini A, Rososchansky J, Gatti G et al (2009) The surgical margin status after breast-conserving surgery: discussion of an open issue. Breast Cancer Res Treat 113:397-402. doi:10.1007/ s10549-008-9929-0
7. Malkas LH, Herbert BS, Abdel-Aziz W et al (2006) A cancerassociated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci USA 103:19472-19477. doi:10.1073/pnas.0604614103 (Pubitemid 46026055)
8. McCann A, Johnston PA, Dervan PA, Gullick WJ, Carney DN (1989) c-erB-2 oncoprotein expression in malignant and nonmalignant breast tissue. Ir J Med Sci 158:137-140 (Pubitemid 19178836)
9. Morrow M (2009) Breast conservation and negative margins: how much is enough? Breast 18(Suppl 3):S84-S86. doi:10.1016/ S0960-9776(09) 70279-6
10. Munhoz AM, Montag E, Arruda E et al (2009) Immediate reconstruction following breast-conserving surgery: management of the positive surgical margins and influence on secondary reconstruction. Breast 18:47-54. doi:10.1016/j.breast.2008. 10.005
11. Royds JA, Iacopetta B (2006) p53 and disease: when the guardian angel fails. Cell Death Differ 13:1017-1026. doi:10.1038/sj.cdd. 4401913
12. Yamashiro N, Tozaki M, Ogawa T et al (2009) Preoperative MRI marking technique for the planning of breast-conserving surgery. Breast Cancer 16:223-228. doi:10.1007/s12282-008-0088-2
13. Zavagno G, Goldin E, Mencarelli R et al (2008) Role of resection margins in patients treated with breast conservation surgery. Cancer 112:1923-1931. doi:10.1002/cncr.23383 (Pubitemid 351574067)